Press Releases Events & Presentations Event Details STI & HIV 2025 World Congress Jul 26 - Jul 30, 2025 Supporting Materials ABI-1179, a Novel, Orally Administered, Long-Acting HSV Helicase-Primase Inhibitor: Interim Analysis of Safety and Pharmacokinetic Data From a Phase 1a Study in Healthy Participants 531.8 KB ABI-5366, a Novel, Oral, Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor: Interim Safety and Pharmacokinetic Results From a Phase 1a Study in Healthy Participants 333.4 KB ABI-5366, a Potent HSV Helicase-Primase Inhibitor, with Potential for Weekly or Monthly Oral Dosing for Recurrent Genital Herpes 345.8 KB ABI-5366 and ABI-1179 – Estimating Genital Herpes Prevalence and Treatment Patterns Among US Healthcare–Engaged Individuals: Insights From Claims Data 283.1 KB Shareholder Tools Print Email Alerts RSS News Feeds Search Investors
STI & HIV 2025 World Congress Jul 26 - Jul 30, 2025 Supporting Materials ABI-1179, a Novel, Orally Administered, Long-Acting HSV Helicase-Primase Inhibitor: Interim Analysis of Safety and Pharmacokinetic Data From a Phase 1a Study in Healthy Participants 531.8 KB ABI-5366, a Novel, Oral, Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor: Interim Safety and Pharmacokinetic Results From a Phase 1a Study in Healthy Participants 333.4 KB ABI-5366, a Potent HSV Helicase-Primase Inhibitor, with Potential for Weekly or Monthly Oral Dosing for Recurrent Genital Herpes 345.8 KB ABI-5366 and ABI-1179 – Estimating Genital Herpes Prevalence and Treatment Patterns Among US Healthcare–Engaged Individuals: Insights From Claims Data 283.1 KB
ABI-1179, a Novel, Orally Administered, Long-Acting HSV Helicase-Primase Inhibitor: Interim Analysis of Safety and Pharmacokinetic Data From a Phase 1a Study in Healthy Participants 531.8 KB
ABI-5366, a Novel, Oral, Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor: Interim Safety and Pharmacokinetic Results From a Phase 1a Study in Healthy Participants 333.4 KB
ABI-5366, a Potent HSV Helicase-Primase Inhibitor, with Potential for Weekly or Monthly Oral Dosing for Recurrent Genital Herpes 345.8 KB
ABI-5366 and ABI-1179 – Estimating Genital Herpes Prevalence and Treatment Patterns Among US Healthcare–Engaged Individuals: Insights From Claims Data 283.1 KB
